2022 Thrive Initiative
2022 Thrive Initiative AwardEES & Projects
- Advance existing MPN research projects the applicant is engaged in currently.
- Foster the growth and development of early-career MPN researchers.
- Attract established researchers that are new to the MPN field.
- Encourage collaborative translational projects with near-term clinical impact.
Four projects awarded, up to $100,000 each over one year.
Objective: Preserve and advance existing promising MPN research that would otherwise languish.
John D. Crispino, PhD, MBA, St. Jude Children’s Research Hospital
Project title: “Aberrant Megakaryopoiesis in the MPNs”
- • A major goal of the lab is to better understand the factors that drive MPN MKs toward ET versus MF and develop strategies to prevent or slow disease progression
- • The is to use this latest information to develop therapeutic agents/strategies to prevent or inhibit aberrant MKs development and progression to MF
Michal Bar-Natan, Icahn School of Medicine at Mt. Sinai
Project title: “Harnessing the immune system to target Calreticulin mutant myeloproliferative neoplasms”
- • This research team has developed a vaccine that targets mutated CALR with the goal of enhancing the immune response in MPN patients
- • This project represents the initial testing of this vaccine in a clinical trial in MPN patients
Nicole Kucine, MD, MS, Weill Cornell Medicine
Project title: “Analysis of Mutational Spectrum in Pediatric Myeloproliferative Neoplasms”
- • Children and young adults are diagnosed with MPNs and the genetic factors contributing to disease onset and progression have not been well studied
- • Dr. Kucine has developed a database of children and young adults with MPNs and will use this funding to continue to follow and expand this patient population to compare and contrast the role of genetics in this patient population versus that already known in adults
Joe Scandura, MD, PhD, Weill Cornell Medicine
Project title: “Tracking MPN Fitness to speed development of disease modifying agents for MPNs”
- • This project will develop a new surrogate clinical measure called “MPN Fitness” that can potentially predict major events like thrombosis and disease progression and response to therapy
- • The goal of this project is to further simplify the MPN fitness procedure making it more user friendly and robust for future clinical trials and further validation
Six projects awarded, up to $200,000 each over two years
Objective: Provide an opportunity for junior investigators to compete exclusively with their peers for an MPNRF grant and enhance their capacity for future funding in the MPN field.
Idoroenyi Amanam, MD, MS, City of Hope National Medical Center
Project title: “Investigation of IL-1RAP in Myeloproliferative Neoplasms: Potential novel anti-leukemic therapy”
- • Immunotherapies such as Bispecific antibodies (BsAb) such as blimatomomab that involve T cells are shown to be effective in cancers such as leukemia
- • Amanam group proposes to reduce the toxicity to normal stem cells by using BsAb to target the cancer stem cells expressing proteins called IL1RAP and CD3 that is present on MPN stem cells
Najla Arshad, PhD, Yale University School of Medicine
Project title: “Development of nanobody-based targeted therapy for myeloproliferative neoplasms”
- • Around 35% of MPNs are driven by a mutant protein called calreticulin (CALR), which is responsible for protein folding and antigen presentation by major histocompatibility class I (MHC-I) complexes
- • This group plans to target the pathogenic CALR-FS-TPO-R [frameshift mutations in CALR (CALR-FS) and thrombopoietin growth factor receptor (TPO-R)] interaction and MPN-associated peptide-MHC-I complexes, and then other unidentified cell surface alterations
Joan Beckman, MD, PhD, University of Minnesota, Twin Cities
Project title: “Role of Gas6-Axl-MERTK in Myeloproliferative Neoplasm Thrombosis”
- • This project will explore a potential signaling pathway driving thrombosis in MPN patients
- • This research has near term implications as there is the potential for rapid translation of results into a clinical trial with an established late-stage investigational agent called bemcentinib
Sahand Hormoz, PhD, Dana-Farber Cancer Institute
Project title: “A new mouse model of the early phase of myeloproliferative neoplasms for probing disease heterogeneity”
- • This project seeks to develop a mouse model to study the factors that drive different disease outcomes in people who have MPN driver mutation, JAK2V617F, that can lead to PV and other MPNs
- • This model system, if successful, will enable the testing of therapeutic strategies can potentially delay or prevent the onset of disease
Shannon Elf, PhD, University of Chicago
Project title: “Dissecting the pathophysiological role of GLUT1 in driving type 1 CALR-mutated myeloproliferative neoplasms”
- • This group proposes to understand how Type-1 CALR mutation leads to metabolic changes, including up-regulated glucose uptake in mutant cells, and how targeting it can specifically kill type 1 CALR-mutated MPN cells while sparing normal ones.
- • They are testing this treatment modality in triple negative breast cancer to determine whether this is a viable treatment option for MPN patients
Shinobu Matsuura, DVM, PhD, Boston University School of Medicine
Project title: “Targeting the JAK2V617F Hematopoietic Stem Cell Through Integrins-Based Combination”
- • This group has previously shown that an anti-beta 1 integrin (activates JAK2) inhibitory antibody given to mice with MPN significantly reduced the mutated stem cells numbers with negligible effects in normal mice.
- • The goal of this project is to determine if this antibody therapeutic approach can lead to complete MPN stem cell exhaustion (with potentially curative implications) and be a viable and safe therapy.
One project awarded, up to $200,000 over two years.
Objective: To provide a competitive funding environment for researchers new to the MPN field bringing novel ideas into MPN research.
Ioannis Aifantis, PhD New York University Grossman School of Medicine
Project title: “Dissecting and targeting transcriptional and epigenetic regulation in advanced myelofibrosis (MF)”
- • Their previous studies show that blood formation in the spleen is biased toward the myeloid lineages therefore lacking normal blood cell formation
- • The project focused on understanding the controlling factors for this bias and testing therapeutic approaches to MF
Please email any questions to firstname.lastname@example.org